BIOMARK DIAGNOSTICS Aktie

>Performance

1 Woche: +2,8%

1 Monat: +8,8%

3 Monate: +19,4%

6 Monate: +120,2%

1 Jahr: +148,3%

laufendes Jahr: +19,4%

>BIOMARK DIAGNOSTICS Aktie

Name:

BIOMARK DIAGNOSTICS INC.

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA09073K1084 / A12EKB

Symbol/ Ticker:

20B (Frankfurt)

Kürzel:

FRA:20B, ETR:20B, 20B:GR

Index:

Webseite:

https://www.biomarkdiagno..

Profil:

Biomark Diagnostics Inc. is a biotechnology company focused on the development of innovative cancer diagnostic solutions. The primary goal of Biomark is to enhance early detection and monitoring of cancer through non-invasive, cost-effective liquid b..
>Volltext..

Marktkapitalisierung:

37.94 Mio. EUR

Unternehmenswert:

37.59 Mio. EUR

Umsatz:

0.06 Mio. EUR

EBITDA:

-0.98 Mio. EUR

Nettogewinn:

-1.07 Mio. EUR

Gewinn je Aktie:

-0.01 EUR

Schulden:

0.45 Mio. EUR

Liquide Mittel:

0.31 Mio. EUR

Operativer Cashflow:

-0.9 Mio. EUR

Bargeldquote:

1.04

Umsatzwachstum:

-45.32%

Gewinnwachstum:

17.23%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOMARK DIAGNOSTICS, BIOMARK DIAGNOSTIC

Letzte Datenerhebung:

05.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 105.09 Mio. St.

Frei handelbar: 46.34%

Leerverk. Aktien: -

Rückkaufquote: -4.87%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: 728.17

KBV: 128.9

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -504.58%

Gewinnmarge: -1852.06%

Operative Marge: -2305.04%

Managementeffizenz:

Gesamtkaprendite: -112.84%

Eigenkaprendite: -

>Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>Chart & Kurs - Stuttgart

>Alle News

15.01.26 - 14:42	BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for ......

31.12.25 - 14:42	BioMark Diagnostics, Inc.: BioMark: 2025 Achievements & 2026 Vision (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy......

30.12.25 - 14:48	BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy......

23.12.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cance......

01.12.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for ......

12.11.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leadin......

07.10.25 - 14:48	BioMark Diagnostics, Inc.: BioMark′s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for e......

29.09.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Secures Key Patents in Asia′s Largest Markets for Early Lung Cancer Liquid Biopsy (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies fo......

12.08.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early ca......

05.08.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early can......

30.07.25 - 14:48	BioMark Diagnostics, Inc.: BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026 (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tes......

28.07.25 - 11:15

XFRA: SPAFR - HANDELSUNTERBRECHUNG IN DIVERSEN AUSLANDSAKTIEN - TEIL 7 (XETRA)

AU0000315533 AU0000317281 AU0000330474 AU0000332553 AU0000333486 AU0000336018 AU0000336679 AU0000338311 AU0000339426 AU0000341232 AU0000362105 AU0000365637 AU0000380420 AU0000381691 AU0000390387 AU0000394082 AU0000396905 AU0000XINAJ0 BE0003470755 BE0974276082 BMG1739E1084 BMG2178K1009 BMG2415A1137 BMG243851091 BMG3000U1009 BMG3602E1084 BMG4593F1389 BMG4R86G1074 BMG668971101 BMG6716L1081 CA00135V1094 CA00149L1058 CA0030691012 CA00547Y2042 CA00775H1055 CA00784W1014 CA00791P1071 CA0091204036 CA01450V1040 CA0213611001 CA02136K1084 CA02156R1082 CA02215R1073 CA02311U1030 CA0272592092 CA0307361026 CA03078N2095 CA03268Y1060 CA03464C1068 CA04016E2024 CA04051N1096 CA0422791099 CA04364G1063 CA0468241082 CA04964G1000 CA04965P2089 CA05277B2093 CA0545211090 CA05478T2074 CA05577W2004 CA0566001099 CA06766T1075 CA07012B4038 CA0712052079 CA07135M2031 CA0765881028 CA0832971018 CA08345Q2080 CA08825T1021 CA0888931023 CA08916W1059 CA0898041086 CA09068G1046...

20.05.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cance......

12.05.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cance......

08.05.25 - 14:51	BioMark Diagnostics announces uplisting to OTCQB venture market (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.25 - 14:43	BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Uplisting to OTCQB Venture Market (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests......

31.03.25 - 14:42	BioMark Diagnostics, Inc.: BioMark Announces the Final Closing of Oversubscribed Private Placement (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early ......

26.03.25 - 13:48	BioMark Diagnostics, Inc.: BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform (Newsfile)
	Vancouver, British Columbia--(Newsfile Corp. - March 26, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, ......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram